KEPPRA

Formula & Concentration

KEPPRA® (levetiracetam) 250 mg, 500 mg, 750 mg, and 1000 mg tablets

KEPPRA® (levetiracetam)  100 mg/mL oral solution

Manufacturer

UCB

Indications

  • KEPPRA is indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy.
  • KEPPRA is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy.
  • KEPPRA is indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy.

Product Options

Package Size

NDC #

Presentation

Oral solution, 100 mg / mL

50474-0001-48

Bottle

Injection for intravenous use, 500 mg / 5 mL

50474-0002-63

Vial

250 mg

50474-0594-40

Bottle

500 mg

50474-0595-40

Bottle

750 mg

50474-0596-40

Bottle

1000 mg

50474-0597-66

Bottle

XR, 500 mg

50474-0598-66

Bottle

XR, 750 mg

50474-0599-66

Bottle

Shelf Life and Storage

Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature.]